Compare SNDL & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDL | TRDA |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.6M | 404.4M |
| IPO Year | 2019 | 2021 |
| Metric | SNDL | TRDA |
|---|---|---|
| Price | $1.60 | $11.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.9M | 229.0K |
| Earning Date | 03-17-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $683,170,243.00 | $61,520,000.00 |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | $3.41 | $3.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.43 | N/A |
| 52 Week Low | $1.15 | $4.93 |
| 52 Week High | $2.89 | $14.27 |
| Indicator | SNDL | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 41.48 | 55.09 |
| Support Level | $1.45 | $10.34 |
| Resistance Level | $1.67 | $12.18 |
| Average True Range (ATR) | 0.07 | 0.75 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 60.00 | 59.65 |
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.